Impact of thymidine phosphorylase-expressing macrophages for surgical margin in partial nephrectomy

Urologia Internationalis

Volumn 82, Issue 4, 2009, Pages 388-393

  Liu, Hongming ^a   Takayama, Tatsuya ^a   Ogawa, Hiroshi ^b   Kai, Fumitake ^a   Sugiyama, Takayuki ^a   Aoki, Takahiro ^a   Harada, Masaki ^a   Otsuka, Atsushi ^a   Furuse, Hiroshi ^a   Kurita, Yutaka ^a   Mugiya, Soichi ^a   Ushiyama, Tomomi ^a   Ozono, Seiichiro ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

Author keywords

Macrophage; Margin; Partial nephrectomy; Renal cell carcinoma; Thymidine phosphorylase

Indexed keywords

THYMIDINE PHOSPHORYLASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CELL INFILTRATION; CLINICAL ARTICLE; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MACROPHAGE; MALE; PARTIAL NEPHRECTOMY; PATIENT SAFETY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MACROPHAGES; MALE; MIDDLE AGED; NEPHRECTOMY; THYMIDINE PHOSPHORYLASE;

EID: 67650302646     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218525     Document Type: Article

References (27)

1. Senga Y, Ozono S, Nakazawa H, Nagamori S, Marumo K, Horie S, Onishi T, Miyao N, Na-kao M, Iga rashi T, Tsu sh ima T, Ha segawa M, Murai M; the Japanese Society of Renal Cancer (JSRC): Surgical outcomes of partial nephrectomy for renal cell carcinoma: a joint study by the Japanese Society of Renal Cancer. Int J Urol 2007;14:284-288.
2. Herr HW: A history of partial nephrectomy for renal tumors. J Urol 2005;173:705-708.
3. Fergany AF, Hafez KS, Novick AC: Longterm results of nephron sparing surgery for localized renal cell carcinoma: 10-year follow-up. J Urol 2000; 163:442-445.
4. Piper NY, Bishoff JT, Magee C, Haffron JM, Flanigan RC, Mintiens A, van Poppel HP, Thompson IM, Harmon WJ: Is a 1-cm margin necessary during nephron-sparing surgery for renal cell carcinoma? Urology 2001; 58:849-852.
5. Sutherland SE, Resnick MI, Maclennan GT, Goldman HB: Does the size of the surgical margin in partial nephrectomy for renal cell cancer rea l ly matter? J Urol 2002; 167:61-64.
6. Li QL, Guan HW, Zhang QP, Zhang LZ, Wang FP, Liu YJ: Optimal margin in nephron-sparing surgery for renal cell carcinoma 4 cm or less. Eur Urol 2003; 44:448-451.
7. Galfano A, Novara G, Iafrate M, Gavalleri S, Martignoni G, Gardiman M, D'Elia C, Patard JJ, Artibani W, Ficarra V: Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urol Int 2008; 80: 113-123.
8. Takayama T, Mugiya S, Sugiyama T, Aoki T, Furuse H, Liu HM, HiranoY, Kai F, Ushiyama T, Ozono S: High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma. Jpn J Clin Oncol 2006; 36:564-569.
9. Imazono Y, Takebayashi Y, Nishiyama K, Ak iba S, Miyadera K, Yamada Y, Ak iyama S, Ohi Y: Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 1997; 15:2570-2578.
10. Kinsui H, Ueda T, Suzuki H, Isaka S, Sekita N, Komiya A, Tobe T, Yamanishi T, Akakura K, Ichikawa T, Igarashi T, Ito H: Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method. Jpn J Cancer Res 2002; 93:340-345.
11. Mizutani Y, Wada H, Yoshida O, Fukushima M, Kawaguchi A, Nakao M, Miki T: The significance of thymidine phosphorylase/plate-let-derived endothelial cell growth factor activity in renal cell carcinoma. Cancer 2003; 98:730-736.
12. Takabayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, Aoki D, Okumura H, Yamada Y, Akiyama S, Aikou T: The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 1996; 32: 1227-1232.
13. Yao Y, Kubot a T, Sato K, K itai R: Macrophage infiltration-associated thymidine phosphorylase expression correlates with increased microvessel density and poor prognosis in astrocytic tumors. Clin Cancer Res 2001;7: 4021-4026.
14. Froehner M, Hakenberge OW, Wirth MP: Molecular therapy in urologic oncology. Urol Int 2007;79:1-7.
15. Union Internationale Contre le Cancer: TNM Atlas, ed 5. Berlin, Springer, 2002.
16. Japanese Urological Association, The Japanese Society of Pathology, and Japan Radiological Society: General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma, ed 3. Tokyo, Kanehara, 1999.
17. Vermooten V: Indications for conservative surgery in certain renal tumors: a study based on the growth pattern of the renal cell carcinoma. J Urol 1950; 64: 200-208.
18. Butler BP, Novick AC, Miller DP, Campbell SA, Licht MR: Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery. Urology 1995; 45: 34-40.
19. Puppo P, Introini C, Calvi P, Naselli A: Longterm results of excision of small renal cancer surrounded by a minimal layer of grossly normal parenchyma: review of 94 cases. Eur Urol 2004; 46:477-481.
20. Martorana G, Bertaccini A, Concetti S, Franceschelli A, Schiavina R, Severini E, Sanguedolce F, Giberti C, Belgrano E, Carmignani G: Nephron-sparing surgery for renal cell carcinoma: state of the art and 10 years of multicentric experience. Eur Urol Suppl 2006; 5:600-609.
21. Mitchell RE, Gilbert SM, Murphy AM, Olsson CA, Benson MC, McKiernan JM: Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology 2006; 67:260-264.
22. Dash A, Vickers AJ, Schachter LR, Bach AM, Snyder ME, Russo P: Comparison of outcomes in elective partial vs. radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int 2006; 97:939-945.
23. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M, Yamada Y: Angiogenic factor. Nature 1992; 356: 668.
24. Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ: The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 1997;57:570-572.
25. Toi M, Ueno T, Matsumoto H, Saji H, Funata N, Koike M, Tominaga T: Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin Cancer Res 1999; 5:1131-1137.
26. Wada S, Yoshimura R , Naga nu ma T, Yoshida N, Narita K, Ikemoto S: Thymidine phosphorylase levels as a prognostic factor in renal cell carcinoma. BJU International 2003; 91:105-108.
27. Ezaki T, Ikegami T, Maeda T, Yamada T, Ishida T, Hashizume M, Maehara Y: Prognosis value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma. Int J Clin Oncol 2005;10:171-176.